NeXell Therapeutics was founded with a clear purpose: to overcome the limitations of current cell therapies and extend their benefits to the vast majority of cancer patients who cannot yet benefit from these revolutionary treatments.
Drawing from Dr. Ahmadi's extensive expertise in cell therapy, NeXell Therapeutics recognized that the key to expanding cell therapy's reach lies in an entirely new approach: engineering smarter immune cells—cells that can regulate themselves, adapt to changing conditions, and overcome the hostile tumor microenvironment found in solid tumors.
Today, we're pioneering a new generation of immune cell therapies by equipping immune cells with built-in intelligence and multi-level auto-switches, enabling them to self-regulate and dynamically adjust their activity in response to the diverse and evolving nature of cancers.